1312 related articles for article (PubMed ID: 12435255)
1. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Wright JT; Bakris G; Greene T; Agodoa LY; Appel LJ; Charleston J; Cheek D; Douglas-Baltimore JG; Gassman J; Glassock R; Hebert L; Jamerson K; Lewis J; Phillips RA; Toto RD; Middleton JP; Rostand SG;
JAMA; 2002 Nov; 288(19):2421-31. PubMed ID: 12435255
[TBL] [Abstract][Full Text] [Related]
2. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
Agodoa LY; Appel L; Bakris GL; Beck G; Bourgoignie J; Briggs JP; Charleston J; Cheek D; Cleveland W; Douglas JG; Douglas M; Dowie D; Faulkner M; Gabriel A; Gassman J; Greene T; Hall Y; Hebert L; Hiremath L; Jamerson K; Johnson CJ; Kopple J; Kusek J; Lash J; Lea J; Lewis JB; Lipkowitz M; Massry S; Middleton J; Miller ER; Norris K; O'Connor D; Ojo A; Phillips RA; Pogue V; Rahman M; Randall OS; Rostand S; Schulman G; Smith W; Thornley-Brown D; Tisher CC; Toto RD; Wright JT; Xu S;
JAMA; 2001 Jun; 285(21):2719-28. PubMed ID: 11386927
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure control, drug therapy, and kidney disease.
Contreras G; Greene T; Agodoa LY; Cheek D; Junco G; Dowie D; Lash J; Lipkowitz M; Miller ER; Ojo A; Sika M; Wilkening B; Toto RD;
Hypertension; 2005 Jul; 46(1):44-50. PubMed ID: 15897360
[TBL] [Abstract][Full Text] [Related]
4. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
Lea J; Greene T; Hebert L; Lipkowitz M; Massry S; Middleton J; Rostand SG; Miller E; Smith W; Bakris GL
Arch Intern Med; 2005 Apr; 165(8):947-53. PubMed ID: 15851648
[TBL] [Abstract][Full Text] [Related]
5. Lessons from the African-American Study of Kidney Disease and Hypertension: an update.
Toto RD
Curr Hypertens Rep; 2006 Oct; 8(5):409-12. PubMed ID: 16965728
[TBL] [Abstract][Full Text] [Related]
6. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.
Norris K; Bourgoigne J; Gassman J; Hebert L; Middleton J; Phillips RA; Randall O; Rostand S; Sherer S; Toto RD; Wright JT; Wang X; Greene T; Appel LJ; Lewis J;
Am J Kidney Dis; 2006 Nov; 48(5):739-51. PubMed ID: 17059993
[TBL] [Abstract][Full Text] [Related]
8. The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?
Sica DA
J Clin Hypertens (Greenwich); 2003; 5(2):159-67. PubMed ID: 12671332
[TBL] [Abstract][Full Text] [Related]
9. ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial.
Douglas JG; Agodoa L
Kidney Int Suppl; 2003 Feb; (83):S74-6. PubMed ID: 12864879
[TBL] [Abstract][Full Text] [Related]
10. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive drugs and renal protection.
Fukuda M; Usami T; Yoshida A; Kimura G
JAMA; 2003 Mar; 289(9):1102-3; author reply 1103. PubMed ID: 12622571
[No Abstract] [Full Text] [Related]
12. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.
Thornley-Brown D; Wang X; Wright JT; Randall OS; Miller ER; Lash JP; Gassman J; Contreras G; Appel LJ; Agodoa LY; Cheek D
Arch Intern Med; 2006 Apr; 166(7):797-805. PubMed ID: 16606818
[TBL] [Abstract][Full Text] [Related]
13. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).
Gassman JJ; Greene T; Wright JT; Agodoa L; Bakris G; Beck GJ; Douglas J; Jamerson K; Lewis J; Kutner M; Randall OS; Wang SR
J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S154-65. PubMed ID: 12819322
[TBL] [Abstract][Full Text] [Related]
14. Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial.
Davis EM; Appel LJ; Wang X; Greene T; Astor BC; Rahman M; Toto R; Lipkowitz MS; Pogue VA; Wright JT;
Hypertension; 2011 Jun; 57(6):1061-8. PubMed ID: 21555676
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.
Appel LJ; Wright JT; Greene T; Kusek JW; Lewis JB; Wang X; Lipkowitz MS; Norris KC; Bakris GL; Rahman M; Contreras G; Rostand SG; Kopple JD; Gabbai FB; Schulman GI; Gassman JJ; Charleston J; Agodoa LY;
Arch Intern Med; 2008 Apr; 168(8):832-9. PubMed ID: 18443258
[TBL] [Abstract][Full Text] [Related]
16. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
[TBL] [Abstract][Full Text] [Related]
17. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients.
Velussi M; Brocco E; Frigato F; Zolli M; Muollo B; Maioli M; Carraro A; Tonolo G; Fresu P; Cernigoi AM; Fioretto P; Nosadini R
Diabetes; 1996 Feb; 45(2):216-22. PubMed ID: 8549868
[TBL] [Abstract][Full Text] [Related]
18. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber MA; Franklin S; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T;
Ann Intern Med; 2006 Feb; 144(3):172-80. PubMed ID: 16461961
[TBL] [Abstract][Full Text] [Related]
20. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
